This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Search Tufts Medicine
The purpose of this study is to collect blood samples for the further development of the diagnostic test Elecsys® Anti TPO II (anti-thyroid peroxidase antibody). This updated test is to aid in the diagnosis of autoimmune thyroid diseases like Hashimoto thyroiditis or Graves’ disease. In blood of patients suffering from these diseases, antibodies like anti-TPO are generally elevated. In the This study, the patient's blood sample will be analyzed with the updated Elecsys® Anti-TPO II test.
Utilize fresh tumor tissue to aid the development of future therapies for brain cancer.
Briefly, a cell immunotherapy consisting of a patient’s autologous glioblastoma tumor cells, called ‘IGV-001’, is being tested in clinical trials. In order to advance clinical and product development of IGV-001, Imvax is seeking access to patient material to test key product parameters in a laboratory setting.